RetinalGenix Technologies Inc. (RTGN) Fair Value 2026

RTGN · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.5 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (34/100)

Quick Summary — As of 2026-08-27, RetinalGenix Technologies Inc. (RTGN) trades at $4.00. QOC: 3.5/10. Value Trap Risk: 34/100 (LOW). 0/13 models active.

Key Facts

Ticker
RTGN
Price
$4.00
Quality Score
3.5/10
Value Trap Risk
34/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 3.5/10 signals weak fundamentals

What Fair Value Does Each Model Give RTGN?

0 Intrinsic Value Models vs. Current Price ($4.00)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is RetinalGenix Technologies Inc. (RTGN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, RetinalGenix Technologies Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About RTGN?

0 of 13 models are currently active for RTGN. See which stocks rank higher →

How Does RTGN Rank in Medical Devices?

Among 157 Medical Devices stocks, RTGN ranks #152 by Quality of Company score. CirclFi's QOC score of 3.5/10 evaluates 32 fundamental signals. A score of 3.5 signals below-average fundamentals.

See all Most Undervalued Medical Devices Stocks →

Within the Medical Devices space, RetinalGenix Technologies Inc. competes in an environment where revenue per drug often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is RTGN a Value Trap?

CirclFi's Value Trap algorithm assigns RTGN a score of 34/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for RetinalGenix Technologies Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, RetinalGenix Technologies Inc. is rated at 3.5/10. This weak-tier score exhibits fundamental weaknesses that warrant careful scrutiny.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every RTGN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy RetinalGenix Technologies Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

LMRILumexa Imaging Holdings, Inc.QOC 3.5WOKWORK Medical Technology Group LTDQOC 2.8GCTKGlucoTrack, Inc.QOC 3.6ICCMIceCure Medical LtdQOC 2.8ODYYOdyssey Health, Inc.QOC 3.7BDMDBaird Medical Investment Holdings LimitedQOC 2.8SIBNSI-BONE, Inc.QOC 7.5BFLYButterfly Network, Inc.QOC 6.4GTHPGuided Therapeutics, Inc.QOC 5.5IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: LMRI · WOK · GCTK · ICCM · ODYY · BDMD · SIBN · BFLY · GTHP · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to RTGN?

7 companies across all industries closest to RTGN’s Quality of Company score of 3.5/10.

OXLCOxford Lane Capital Corp.QOC 3.5GENBGenerate Biomedicines, Inc.QOC 3.5SKTTanger Inc.QOC 3.5NMHINature's Miracle Holding Inc.QOC 3.5SBMTSilver Bow Mining Corp.QOC 3.5EDGMEdgeMode, Inc.QOC 3.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: OXLC · GENB · SKT · NMHI · SBMT · EDGM · NVDA

Where Does RTGN Sit in CirclFi's Medical Devices Rankings?

RTGN is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About RetinalGenix Technologies Inc.’s Valuation?

What is RetinalGenix Technologies Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for RetinalGenix Technologies Inc. (RTGN). The Quality of Company score is 3.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is RTGN overvalued or undervalued right now?

At $4.00, 0 of 0 active models suggest RTGN may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits RetinalGenix Technologies Inc.'s business model in Medical Devices.

What does a Quality of Company score of 3.5 mean for RTGN?

RetinalGenix Technologies Inc.'s QOC of 3.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on RTGN?

CirclFi analyzes RTGN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is RTGN a value trap in 2026?

RetinalGenix Technologies Inc.'s Value Trap score is 34/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns RetinalGenix Technologies Inc. (RTGN) a Quality of Company score of 3.5/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/RTGN/ · Methodology
Primary sources for this RTGN valuation
  • Financial statements: RetinalGenix Technologies Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001836295) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for RTGN as of ; valuations recomputed .